Baird lowered the firm’s price target on Karyopharm to $8 from $10 and keeps an Outperform rating on the shares. The firm said they reported 3Q results, including an in-line quarter for Xpovio, reaffirmed 2023 guidance, and broad pipeline progress. Importantly, its three Phase 3 studies of monotherapy in endometrial maintenance, first-line SOC combo in myelofibrosis, and an all-oral regimen in MM are all advancing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KPTI:
- Karyopharm price target lowered to $5 from $8 at Barclays
- Karyopharm backs 2023 revenue view $145M-$160M, consensus $151.17M
- Karyopharm reports Q3 EPS (30c), consensus (28c)
- Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Karyopharm signs clinical trial collaboration with Bristol Myers in myeloma